{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:58:51Z","timestamp":1791331131794,"version":"4.3.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,2,28]],"date-time":"2008-02-28T00:00:00Z","timestamp":1204156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,2,28]],"date-time":"2008-02-28T00:00:00Z","timestamp":1204156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1038\/sj.jhh.1002328","type":"journal-article","created":{"date-parts":[[2008,2,28]],"date-time":"2008-02-28T10:38:22Z","timestamp":1204195102000},"page":"338-345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Impact of the therapy by renin\u2013angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension"],"prefix":"10.1038","volume":"22","author":[{"given":"A","family":"Remkov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kratochv\u00edl'ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"\u010eurina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,2,28]]},"reference":[{"key":"BF1002328_CR1","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1161\/01.HYP.36.6.978","volume":"36","author":"LA Seci","year":"2000","unstructured":"Seci LA, Zingaro L, Catena C, Casaccio D, De Marchi S . Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension. Hypertension 2000; 36: 978\u2013985.","journal-title":"Hypertension"},{"key":"BF1002328_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jacc.2004.03.067","volume":"44","author":"SK Nadar","year":"2004","unstructured":"Nadar SK, Blann AD, Kamath S, Beevers DG, Lip GY . Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol 2004; 44: 415\u2013422.","journal-title":"J Am Coll Cardiol"},{"key":"BF1002328_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ijcard.2003.06.002","volume":"94","author":"CGC Spencer","year":"2004","unstructured":"Spencer CGC, Martin SC, Felmden DC, Blann AD, Beevers GD, Lip GYH . Relationship of homocysteine to markers of platelet and endothelial activation in \u2018high risk\u2019 hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Int J Cardiol 2004; 94: 293\u2013300.","journal-title":"Int J Cardiol"},{"key":"BF1002328_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00001721-200201000-00005","volume":"13","author":"GYH Lip","year":"2002","unstructured":"Lip GYH, Blann AD, Edmunds E, Beevers DG . Baseline abnormalities of endothelial function and thrombogenesis in relation to prognosis in essential hypertension. Blood Coagul Fibrinolysis 2002; 13: 35\u201341.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"BF1002328_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000065078","volume":"32","author":"K Sakata","year":"2002","unstructured":"Sakata K, Pawlak R, Urano T, Takada A . Effects of a long-term pharmacological interruption of the renin\u2013angiotensin system on the fibrinolytic system in essential hypertension. Pathophysiol Haemost Thromb 2002; 32: 67\u201375.","journal-title":"Pathophysiol Haemost Thromb"},{"key":"BF1002328_CR6","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1111\/j.1538-7836.2007.02577.x","volume":"5","author":"AWJH Dielis","year":"2007","unstructured":"Dielis AWJH, Smid M, Spronk HMH, Houben AJHM, Hamuly\u00e1k K, Kroon AA et al. Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients. J Thromb Haemost 2007; 5: 1509\u20131515.","journal-title":"J Thromb Haemost"},{"key":"BF1002328_CR7","first-page":"1","volume":"66","author":"MP Curran","year":"2003","unstructured":"Curran MP, McCormack PL, Simpson D, Perindopril. A review of its use in patients with or at risk of developing coronary artery disease. Drugs 2003; 66: 1\u201321.","journal-title":"Drugs"},{"key":"BF1002328_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2165\/00003495-200666010-00004","volume":"66","author":"AJ Battershill","year":"2006","unstructured":"Battershill AJ, Scott LJ, Telmisartan. A review of its use in the management of hypertension. Drugs 2006; 66: 51\u201383.","journal-title":"Drugs"},{"key":"BF1002328_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2478\/s11696-007-0010-y","volume":"61","author":"M Remko","year":"2007","unstructured":"Remko M . Acidity, lipophilicity, solubility, absorption, and polar surface area of some ACE inhibitors. Chem Pap 2007; 61: 133\u2013141.","journal-title":"Chem Pap"},{"issue":"Part 2","key":"BF1002328_CR10","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/hy0202.103417","volume":"39","author":"JL Zhuo","year":"2002","unstructured":"Zhuo JL, Mendelsohn FAO, Ohishi M . Perindopril alters vascular angiotensin-converting enzyme, AT1 receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002; 39 (Part 2): 634\u2013638.","journal-title":"Hypertension"},{"key":"BF1002328_CR11","first-page":"107","volume":"7","author":"AD Blann","year":"1993","unstructured":"Blann AD, Naqvi T, Waite M, McCollum CN . von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 1993; 7: 107\u2013111.","journal-title":"J Hum Hypertens"},{"key":"BF1002328_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/sj.jhh.1001427","volume":"16","author":"A Remkova","year":"2002","unstructured":"Remkova A, Kratochvilova H . Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension. J Hum Hypertens 2002; 16: 549\u2013555.","journal-title":"J Hum Hypertens"},{"key":"BF1002328_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.amjhyper.2004.09.003","volume":"18","author":"KW Lee","year":"2005","unstructured":"Lee KW, Blann AD, Lip GY . High pulse pressure and nondipping circadian blood pressure in patients with coronary artery disease: relationship to thrombogenesis and endothelial damage\/dysfunction. Am J Hypertens 2005; 18: 104\u2013115.","journal-title":"Am J Hypertens"},{"key":"BF1002328_CR14","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1111\/j.1538-7836.2006.01949.x","volume":"4","author":"UM Vischer","year":"2006","unstructured":"Vischer UM . von Willebrand factor, endothelial dysfunction and cardiovascular disease. J Thromb Haemost 2006; 4: 1186\u20131193.","journal-title":"J Thromb Haemost"},{"key":"BF1002328_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cardiores.2006.10.021","volume":"73","author":"C Ceconi","year":"2007","unstructured":"Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G, et al., on behalf of the EUROPA and the PERTINENT investigators. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237\u2013246.","journal-title":"Cardiovasc Res"},{"key":"BF1002328_CR16","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1161\/01.HYP.0000070956.57418.22","volume":"41","author":"L Ghiadoni","year":"2003","unstructured":"Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281\u20131286.","journal-title":"Hypertension"},{"key":"BF1002328_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2165\/00003495-200262020-00003","volume":"62","author":"S Taddei","year":"2002","unstructured":"Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A . Effects of antihypertensive drugs on endothelial dysfunction\u2014clinical implications. Drugs 2002; 62: 265\u2013284.","journal-title":"Drugs"},{"key":"BF1002328_CR18","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0735-1097(03)00162-1","volume":"41","author":"T Matsumoto","year":"2003","unstructured":"Matsumoto T, Minai K, Horie H, Ohira N, Takashima H, Tarutani Y et al. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol 2003; 41: 1373\u20131379.","journal-title":"J Am Coll Cardiol"},{"key":"BF1002328_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1023\/A:1024394610648","volume":"17","author":"R Ferrari","year":"2003","unstructured":"Ferrari R, Arbustini E, Blann A, Cokkinos D, Kluft C, de Maat MPM et al. PERTINENT\u2013PERindopril\u2013thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. Cardiovasc Drug Ther 2003; 17: 83\u201391.","journal-title":"Cardiovasc Drug Ther"},{"key":"BF1002328_CR20","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"The European trial on reduction of cardiac events with perindopril in stable artery disease Investigators","year":"2003","unstructured":"The European trial on reduction of cardiac events with perindopril in stable artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (EUROPA). Lancet 2003; 362: 782\u2013788.","journal-title":"Lancet"},{"key":"BF1002328_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/09537109877022","volume":"9","author":"A Okruck\u00e1","year":"1998","unstructured":"Okruck\u00e1 A, Pech\u00e1\u0148 J, Kratochv\u00edl'ov\u00e1 H . Effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril on endothelial and platelet functions in essential hypertension. Platelets 1998; 9: 63\u201367.","journal-title":"Platelets"},{"key":"BF1002328_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0953-6205(00)00066-2","volume":"11","author":"A Remkova","year":"2000","unstructured":"Remkova A, Kovacova E, Prikazska M, Kratochvilova H . Thrombomodulin as a marker of endothelium damage in some clinical conditions. Eur J Int Med 2000; 11: 79\u201384.","journal-title":"Eur J Int Med"},{"key":"BF1002328_CR23","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.ehj.2003.08.021","volume":"24","author":"AD Blann","year":"2003","unstructured":"Blann AD, Nadar SK, Lip GYH . The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166\u20132179.","journal-title":"Eur Heart J"},{"key":"BF1002328_CR24","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1532-5415.1999.tb01288.x","volume":"47","author":"S Riondino","year":"1999","unstructured":"Riondino S, Pignatelli P, Pulcinelli FM, Lenti L, Di Veroli C, Marigliano V et al. Platelet hyperactivity in hypertensive older patients is controlled by lowering blood pressure. J Am Geriatr Soc 1999; 47: 943\u2013947.","journal-title":"J Am Geriatr Soc"},{"key":"BF1002328_CR25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1080\/07853890410017386","volume":"36","author":"SK Nadar","year":"2004","unstructured":"Nadar SK, Blann AD, Lip GY . Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. Ann Med 2004; 36: 552\u2013557.","journal-title":"Ann Med"},{"key":"BF1002328_CR26","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1160\/TH04-07-0433","volume":"92","author":"SK Nadar","year":"2004","unstructured":"Nadar SK, Blann AD, Lip GY . Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke. The west Birmingham stroke project. Thromb Haemost 2004; 92: 1342\u20131348.","journal-title":"Thromb Haemost"},{"key":"BF1002328_CR27","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1055\/s-0037-1616131","volume":"86","author":"AD Blann","year":"2001","unstructured":"Blann AD, Lanza F, Galajda P, Gurney D, Moog S, Cazenave JP et al. Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis\u2014the influence of aspirin and cigarette smoking. Thromb Haemost 2001; 86: 777\u2013783.","journal-title":"Thromb Haemost"},{"key":"BF1002328_CR28","first-page":"e17","volume":"36","author":"V Wolff","year":"2005","unstructured":"Wolff V, Aleil B, Giroud M, Lorenzini JL, Meyer N, Wiesel ML et al. Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke. Stroke 2005; 36: e17\u2013e19.","journal-title":"Stroke"},{"key":"BF1002328_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/00207230500120443","volume":"16","author":"E Atalar","year":"2005","unstructured":"Atalar E, Haznedaroglu IC, Kilic H, Ozer N, Coskun S, Ozturk E et al. Increased soluble glycoprotein V concentration during the acute onset of unstable angina pectoris in association with chronic cigarette smoking. Platelets 2005; 16: 329\u2013333.","journal-title":"Platelets"},{"key":"BF1002328_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1160\/TH06-06-0296","volume":"96","author":"B Aleil","year":"2006","unstructured":"Aleil B, Meyer N, Wolff V, Kientz D, Wiesel ML, Gachet C et al. Plasma glycoprotein V levels in the general population: normal distribution, associated parameters and implications for clinical studies. Thromb Haemost 2006; 96: 505\u2013511.","journal-title":"Thromb Haemost"},{"key":"BF1002328_CR31","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1097\/00004872-200307000-00024","volume":"21","author":"Y Kishi","year":"2003","unstructured":"Kishi Y, Ohta S, Kasuya N, Sakita S, Ashikaga T, Isobe M . Perindopril augments ecto-ATP diphosphohydrolase activity and enhances endothelial anti-platelet function in human umbilical vein endothelial cells. J Hypertens 2003; 21: 1347\u20131353.","journal-title":"J Hypertens"},{"key":"BF1002328_CR32","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1097\/00005344-200006000-00012","volume":"35","author":"M Mont\u00f3n","year":"2000","unstructured":"Mont\u00f3n M, Jim\u00e9nez A, N\u00fa\u0148ez A, L\u00f3pez-Blaya A, Farr\u00e9 J, G\u00f3mez J et al. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol 2000; 35: 906\u2013913.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BF1002328_CR33","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1161\/01.CIR.101.3.264","volume":"101","author":"KA Poli","year":"2000","unstructured":"Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I et al. Association of blood pressure with fibrinolytic potential in the Framingham Offspring study. Circulation 2000; 101: 264\u2013269.","journal-title":"Circulation"},{"issue":"Part 2","key":"BF1002328_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1161\/01.HYP.31.1.321","volume":"31","author":"H Tomiyama","year":"1998","unstructured":"Tomiyama H, Kimura Y, Mitsuhashi H, Kinouchi T, Yoshida H, Kushiro T et al. Relationship between endothelial function and fibrinolysis in early hypertension. Hypertension 1998; 31 (Part 2): 321\u2013327.","journal-title":"Hypertension"},{"key":"BF1002328_CR35","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.2337\/diacare.28.9.2211","volume":"28","author":"Y Aso","year":"2005","unstructured":"Aso Y, Wakabayashi S, Yamamoto R, Matsutomo R, Takebayashi K, Inukai T . Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes. Diabetes Care 2005; 28: 2211\u20132216.","journal-title":"Diabetes Care"},{"key":"BF1002328_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.atherosclerosis.2004.07.008","volume":"177","author":"KK Koh","year":"2004","unstructured":"Koh KK, Chung WJ, Ahn JY, Han SH, Kang WC, Seo YH et al. Angiotensin II type receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo controlled study. Atherosclerosis 2004; 177: 155\u2013160.","journal-title":"Atherosclerosis"},{"key":"BF1002328_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S0011-393X(01)80043-6","volume":"62","author":"R Fogari","year":"2001","unstructured":"Fogari R, Zoppi A, Malamani G, Marasi G, Pesce RM, Banderali A et al. Effects of four angiotensin II-receptor antagonists on fibrinolysis in postmenopausal women in hypertension. Curr Ther Res Clin Exp 2001; 62: 68\u201378.","journal-title":"Curr Ther Res Clin Exp"},{"key":"BF1002328_CR38","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/sj.jhh.1001401","volume":"16","author":"TP Erlinger","year":"2002","unstructured":"Erlinger TP, Conlin PR, Macko RF, Bohannon AD, Miller III ER, Moore TJ et al. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis. J Hum Hypertens 2002; 16: 391\u2013397.","journal-title":"J Hum Hypertens"},{"key":"BF1002328_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0167-5273(01)00380-1","volume":"78","author":"FL Li-Saw-Hee","year":"2001","unstructured":"Li-Saw-Hee FL, Beevers DG, Lip GYH . Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial. Int J Cardiol 2001; 78: 241\u2013246.","journal-title":"Int J Cardiol"},{"key":"BF1002328_CR40","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1097\/HJH.0b013e328165d159","volume":"25","author":"J Shao","year":"2007","unstructured":"Shao J, Nangaku M, Inagi R, Kato H, Miyata T, Matsusaka T et al. Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker. J Hypertens 2007; 25: 1643\u20131649.","journal-title":"J Hypertens"},{"issue":"Part 1","key":"BF1002328_CR41","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S0895-7061(99)00145-4","volume":"12","author":"Y Erdem","year":"1999","unstructured":"Erdem Y, Usalan C, Haznedaroglu IC, Altun B, Arici M, Yasavul U et al. Effects of angiotensin-converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 12 (Part 1): 1071\u20131076.","journal-title":"Am J Hypertens"},{"issue":"Part 1","key":"BF1002328_CR42","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0895-7061(01)02340-8","volume":"15","author":"R Fogari","year":"2002","unstructured":"Fogari R, Mugellini A, Zoppi, Corradi L, Preti P, Lazzari P et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15 (Part 1): 316\u2013320.","journal-title":"Am J Hypertens"},{"key":"BF1002328_CR43","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1182\/blood-2003-07-2520","volume":"103","author":"B Saposnik","year":"2004","unstructured":"Saposnik B, Reny JL, Gaussem P, Emmerich J, Aiach M, Gandrille S . A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is candidate risk factor for thrombosis. Blood 2004; 103: 1311\u20131318.","journal-title":"Blood"},{"key":"BF1002328_CR44","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.metabol.2006.04.011","volume":"55","author":"JM Nagel","year":"2006","unstructured":"Nagel JM, Tietz AB, G\u00f5ke B, Parhofer KG . The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism 2006; 55: 1149\u20131154.","journal-title":"Metabolism"},{"key":"BF1002328_CR45","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/00001721-200010000-00008","volume":"7","author":"A Remkov\u00e1","year":"2000","unstructured":"Remkov\u00e1 A, Kratochv\u00edl'ov\u00e1 H . Effect of the angiotensin-converting enzyme inhibitor perindopril on haemostasis in essential hypertension. Blood Coagul Fibrinolysis 2000; 7: 641\u2013644.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"BF1002328_CR46","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S0895-7061(00)00262-4","volume":"13","author":"TK Makris","year":"2000","unstructured":"Makris TK, Stavroulakis GA, Krespi PG, Hatzizacharias AN, Triposkiadis FK, Tsoukala CG et al. Fibrinolytic\/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens 2000; 13: 783\u2013788.","journal-title":"Am J Hypertens"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1002328.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1002328","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1002328.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T18:54:29Z","timestamp":1647543269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1002328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,28]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["BF1002328"],"URL":"https:\/\/doi.org\/10.1038\/sj.jhh.1002328","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,28]]},"assertion":[{"value":"31 August 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2007","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2007","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}